Navegar por autor "Calvo Martínez, Lourdes"

Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo I-III breast cancer registry (1990-2001)

2015- Calvo Martínez, Lourdes

Intermediate study: Observational study about levels of biochemical markers of bone turnover in patients with breast cancer and bone metastases (ZOMAR study)

2011- Calvo Martínez, Lourdes

Lapatinib vs trastuzumab in combination with standard EC-D chemotherapy in the neaodjuvant treatment of HER2+ patients. Results from the GEICAM 2006-14 phase II randomized trial

2011- Calvo Martínez, Lourdes

MERIBEL study: Efficacy of eribulin in first line of taxane-resistant patients with HER2 negative metastatic breast cancer

2015- Calvo Martínez, Lourdes

MicroRNA profile and KRAS status in metastatic colorectal cancer

2011- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; [et al.]

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors

2012- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; [et al.]

Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)

2011- Calvo Martínez, Lourdes; García Mata, Jesús; López López, Rafael; Castellanos Diez, Javier

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

2013- Calvo Martínez, Lourdes

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer

2011- Calvo Martínez, Lourdes

Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study

2011- Antón, A; Ruiz, A; Plazaola, A; Calvo Martínez, Lourdes; Seguí, M. A.; [et al.]

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

2020- Lluch, A.; Barrios, C. H.; Torrecillas, L.; Ruiz-Borrego, M.; Bines, J.; [et al.]

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

2014- Calvo Martínez, Lourdes

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

2019- Antolín Novoa, Silvia; Acea Nebril, Benigno; Albaina Latorre, Luis; Concha Lopez, Angel; Santiago Freijanes, Mª Paz; [et al.]

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

2011- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; [et al.]

Propuesta de una nueva estrategia terapeutica multidisciplinar en la mujer con cancer de mama y afectacion del ganglio centinela

2012- Acea Nebril, Benigno; Antolín Novoa, Silvia; Albaina Latorre, Luis; Juaneda Magdalena, Manuel; Santiago Freijanes, Mº Paz; [et al.]

Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study

2011- Calvo Martínez, Lourdes

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

2019- Lopez-Tarruella, Sara; Escudero, M J; Pollan, Marina; Martin, Miguel; Jara, Carlos; [et al.]

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

2014- Calvo Martínez, Lourdes

Repositorio digital RUNA

Navegar por autor "Calvo Martínez, Lourdes"

Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo I-III breast cancer registry (1990-2001) ﻿

Intermediate study: Observational study about levels of biochemical markers of bone turnover in patients with breast cancer and bone metastases (ZOMAR study) ﻿

Lapatinib vs trastuzumab in combination with standard EC-D chemotherapy in the neaodjuvant treatment of HER2+ patients. Results from the GEICAM 2006-14 phase II randomized trial ﻿

MERIBEL study: Efficacy of eribulin in first line of taxane-resistant patients with HER2 negative metastatic breast cancer ﻿

MicroRNA profile and KRAS status in metastatic colorectal cancer ﻿

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors ﻿

Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC) ﻿

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis ﻿

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer ﻿

Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study ﻿

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) ﻿

Predicting response and survival in chemotherapy-treated triple-negative breast cancer ﻿

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution ﻿

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer ﻿

Propuesta de una nueva estrategia terapeutica multidisciplinar en la mujer con cancer de mama y afectacion del ganglio centinela ﻿

Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study ﻿

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry) ﻿

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial ﻿

Impact on survival of primary tumor resection in women with de novo metastatic breast cancer. The GEICAM Alamo I-III breast cancer registry (1990-2001)

Intermediate study: Observational study about levels of biochemical markers of bone turnover in patients with breast cancer and bone metastases (ZOMAR study)

Lapatinib vs trastuzumab in combination with standard EC-D chemotherapy in the neaodjuvant treatment of HER2+ patients. Results from the GEICAM 2006-14 phase II randomized trial

MERIBEL study: Efficacy of eribulin in first line of taxane-resistant patients with HER2 negative metastatic breast cancer

MicroRNA profile and KRAS status in metastatic colorectal cancer

Micrornas as emerging biomarkers for micrometastasis detection in breast tumors

Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer

Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

Propuesta de una nueva estrategia terapeutica multidisciplinar en la mujer con cancer de mama y afectacion del ganglio centinela

Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009-05 study

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial